FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Recherche/Investigating Angiotensin-(1-7) in Treating Obesity and Insulin Resistance
Retour à la bibliothèque de recherche

Investigating Angiotensin-(1-7) in Treating Obesity and Insulin Resistance

May 25, 2026
Share
Recherche émergente

Basé sur des recherches émergentes. Ces découvertes sont prometteuses mais nécessitent une validation supplémentaire.

À propos de cette analyse

Cet article est un résumé AI-assisté d'un élément de presse ou d'une annonce clinique récemment publié. Il vise à fournir une vue d'ensemble rapide et accessible pour la communauté de recherche en peptides. Pour une précision totale, consultez toujours l'original source ci-dessous.

Investigating Angiotensin-(1-7) in Treating Obesity and Insulin Resistance

A new clinical trial aims to shed light on how a specific peptide, angiotensin-(1-7), can influence metabolism and insulin resistance in obese individuals. This study, sponsored by Vanderbilt University, could provide critical insights into potential therapeutic applications for metabolic disorders such as obesity and type 2 diabetes.

Background

Obesity is increasingly recognized not just as an excess of body fat but also as a condition involving complex hormonal imbalances that can lead to serious health issues like insulin resistance and hypertension. Angiotensin-(1-7) has shown promise in animal studies for its ability to regulate metabolism, potentially reversing these detrimental effects. However, the extent to which this peptide plays a role in human metabolic processes remains unclear.

Vanderbilt University's initiative seeks to bridge this gap by investigating whether angiotensin-(1-7) can improve insulin resistance and other metabolic conditions associated with obesity. This research could pave the way for innovative treatments that leverage peptides like angiotensin-(1-7) to combat metabolic diseases more effectively than current pharmacological options.

Key Details

The clinical trial, identified by ClinicalTrials.gov as NCT02646475, is currently recruiting participants who meet certain criteria related to obesity and insulin resistance. The study will compare the effects of angiotensin-(1-7) against a saline placebo to determine its efficacy in altering metabolic profiles and blood pressure levels.

Participants will be closely monitored throughout the trial period for changes in insulin sensitivity, lipid profiles, and blood pressure readings, among other health indicators. This phase 1 trial is an initial step towards understanding angiotensin-(1-7)'s role in human metabolism, setting the stage for future clinical trials that could lead to FDA-approved peptide therapies.

Key Takeaways

  • Potential Breakthrough: The study aims to confirm whether angiotensin-(1-7) can positively impact insulin resistance and other metabolic conditions associated with obesity.
  • Regulatory Implications: Successful results from this trial could pave the way for further clinical trials, potentially leading to FDA approval of new peptide-based treatments for metabolic diseases.
  • Clinical Application: If proven effective, angiotensin-(1-7) therapy could offer a promising alternative or complement to existing treatments for obesity and type 2 diabetes.
  • Research Impact: This research will contribute valuable data to the growing body of knowledge on how specific peptides influence human metabolism.

What This Means

For researchers and clinicians focused on peptide-based therapies, this study represents an important step forward in understanding the potential clinical applications of angiotensin-(1-7). Positive outcomes could accelerate the development of new treatments for metabolic disorders and enhance our overall comprehension of peptide mechanisms in health and disease. The broader peptide community will be closely watching the results to see if they support further investigation into this promising avenue.

---

Source: ClinicalTrials.gov — Published 2026-05-22

This article is for informational purposes only and does not constitute medical advice.

Note de l'éditeur

Cette analyse a été générée à l'aide d'outils AI et revue par le service éditorial de Peptide Contacts. Bien que nous nous efforcions de maintenir une précision, le contenu généré par l'IA peut contenir des erreurs ou des omissions. Nous encourageons les lecteurs à vérifier les informations auprès de l'original source. source originale pour des détails complets, méthodologie et données.

Peptide Contacts fournit des résumés de recherche curatisés pour des fins d'information uniquement. Ce contenu ne constitue pas un avis médical. Consultez toujours un fournisseur de soins de santé qualifié avant de prendre toute décision concernant votre santé.

Comments

Sign in to join the discussion

Cet article a été généré à l'aide d'IA et peut contenir des inexactitudes. Il est fourni pour des fins d'information uniquement et ne constitue pas un avis médical. Vérifiez toujours les informations auprès de l'original source et consultez un fournisseur de soins de santé qualifié avant de prendre toute décision concernant votre santé.